Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT07723118
PHASE1
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
Sponsor: Mirati Therapeutics Inc.
View on ClinicalTrials.gov
Summary
The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent
Official title: A Phase 1, Single-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-08-05
Completion Date
2026-09-14
Last Updated
2026-09-28
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Adagrasib
Specified dose on specified days
Locations (1)
Local Institution - 0001
Anaheim, California, United States